Business
Respiri (ASX:RSH) share price on watch following FDA approval
The Respiri Ltd (ASX: RSH) share price is on watch today after the company advised it has received United States Food and Drug Administration (FDA) clearance for its Wheezo app.
About Respiri
Respiri is a software-as-a-service (SaaS) company supporting asthma patients to monitor and manage their asthma. The company views that asthma is often under-diagnosed and under-treated, creating a substantial burden to sufferers and their families.
Respiri has created an eHealth SaaS platform, ‘Wheezo’, that uses a device and app to measure, record and monitor asthma symptoms. The device records breath sounds over 30 seconds to be analysed in…
-
General17 hours agoJannik Sinner reveals secret Wimbledon bet that could keep Darren Cahill in his team
-
Noosa News21 hours agoAustralia Zoo reunites with the Ukrainian community
-
Noosa News21 hours ago“Hidden gem”: last chance for renovated bayside homes below $1m
-
Business18 hours agoASX retail share whose ‘fundamentals have deteriorated significantly’: expert